ESCMID 2026 Poster: Exploring the gains: potential economic impact of a rapid, direct from whole-blood-to-report NGS-based diagnostic platform (LiDia-SEQ™) for BSI detection.

Bloodstream infections (BSIs) – leading to sepsis – are one of the deadliest and most costly challenges in modern healthcare. This life threating condition is caused by a wide range of pathogens, with an estimated 49 millions cases globally per year. For every hour in delay of appropriate therapy, risk of mortality is increased by 4-9%. The average cost per hospital stay for sepsis patients is double the average cost per stay across all other conditions. In the USA alone, the annual finical impact on the healthcare system is ~$62 billion. Current standard of care (SoC) approaches like blood culture take a long time (days), cannot detect many pathogens and require additional testing for antimicrobial resistance (AMR) profiling resulting in poorer patient outcomes, extended hospital stays, and escalation in healthcare costs.

DNAe’s BSI/AMR Test on its breakthrough LiDia-SEQ™ platform will offer clinicians and patients a transformative solution: a true sample-to-report NGS-based diagnostic platform that delivers comprehensive results within hours – dramatically faster than the current blood culture dependent SoC.